The 'disease state' results from interactions between intrinsic genetic risks from the host and extrinsic environmental triggers. The genetic component may be simple, involving powerful mutations that inactivate key physiological pathways, or may be complex and heterogeneous, involving combinations of weak genetic lesions whose accumulation phenotypically mimics the effect of a strong mutation. On the other hand, environmental triggers of disease are often complex, heterogeneous, and generally poorly understood. Genetic analysis of susceptibility to infections has proven particularly successful to study how the interface between host and environment causes clinical disease [1] [2] [3] . In infectious diseases, exposure to the environmental trigger (e.g., microbial pathogens) is absolutely required to reveal the host genetic diversity and associated risk. In most extreme cases, selective pressure by lethal microbes has impacted the human genome and has left identifiable genetic fingerprints in areas of endemic disease and following epidemics. Striking examples include the protective role of hemoglobin (Hb) and ACKR1 (DARC) variants against malaria [4] , and of CCR5 deletion against HIV [5] . Dramatic increases in performance and affordability of DNA sequencing now permits genome and wholeexome sequencing (WES) of unique human patients or families that display unusual susceptibility to infections, including pure or syndromic PIDs (see Glossary) [6] [7] [8] . The analysis of such patients has generated a rich genetic data set on the association of rare variants with this group of diseases.
On the other hand, burns, trauma, and environmental insults may disrupt protective tissue barriers and lead to acute or chronic exposure to microbes present at mucosal surfaces and/or Trends Alterations in numbers and activity of immune cells and associated responses result in infectious and inflammatory diseases, which are two of the most common disease areas in humans.
Complex genomic data sets involving hundreds of genes are emerging from genome-wide association studies of susceptibility to common inflammatory diseases, and from whole-exome sequencing of patients suffering from primary immunodeficiencies.
Combined analysis of risk loci for 22 common human inflammatory diseases, and of all primary immunodeficiencies with a known genetic lesion identifies a highly significant genetic overlap between the two groups of diseases.
The cellular and molecular pathways anchored around these genes are therefore required for protection against infections, but their persistent or dysregulated engagement for pathological inflammation in humans.
to appetizing self-antigens. This triggers an inflammatory response in the host, a normal physiological process that involves initial recognition of tissue damage, elimination of the causative lesion, and restoration of tissue homeostasis. Tight regulation of this response is critical: in the presence of persistent tissue injury or sustained microbial insult, overexpression of proinflammatory mediators or insufficient production of anti-inflammatory signals results in immunopathology, including inflammatory or autoimmune disease or allergy. Genetic analysis of susceptibility to acute (sepsis, encephalitis) or chronic inflammatory diseases with possible microbial, autoimmune, and/or autoinflammatory etiologies (inflammatory bowel disease, rheumatoid arthritis, psoriasis to name only a few) has offered additional opportunities to identify important elements of host response to microbial and autoimmune stimuli [9] . Population and family studies have long established a strong genetic component to susceptibility to inflammatory diseases. The recent availability of high-density arrays of polymorphic variants genome-wide (SNP chips) or clustered around 'immune' loci (immunochips) has facilitated the search for genetic determinants (common variants) of susceptibility to inflammatory diseases in humans. Such GWAS in very large cohorts of human patients (>50 000) from different populations, and subsequent meta-analyses of multiple published GWAS of the same disease, have mapped hundreds of genetic loci, each with small effect size, but that together define a rich genetic architecture for several of these complex disorders [10] [11] [12] [13] [14] [15] [16] [17] [18] .
This flurry of technology development has produced very detailed genetic maps for susceptibility to infections and to inflammation, and those have been reviewed elsewhere [19] [20] [21] . Although these are briefly cited herein, the specific focus of this review is on the nature and extent of shared genetic risks across both groups of diseases. Specifically, we discuss how this genetic intersection points to specific genes and pathways that are required for protection against infections but whose sustained engagement in the presence of persistent insult leads to pathological inflammation. We also review how this intersection may provide information on the etiology of certain inflammatory conditions and, conversely, how the two parallel data sets may help identify and validate morbid genes at candidate loci. Finally, this intersection lends support to the hypothesis that strong but rare mutations at specific genes of this overlap may independently cause severe diseases (PIDs), while more subtle modulation by common coding or regulatory variants may contribute to chronic inflammation in the presence of a persistent tissue insult.
Primary Immunodeficiencies
In addition to classical genetic approaches (linkage mapping, immune phenotype-driven candidate gene sequencing, and studies from animal models), WES has dramatically increased the pace at which causative genes are being discovered for PIDs. WES has been most effective in identifying 'morbid' genes in groups of PID patients[ 3 _ T D $ D I F F ] (Mendelian disorders) where the presence of homozygosity for deleterious mutations is likely to be high, including: (i) familial cases, consanguinity, or cases from isolated populations; (ii) patients presenting with particularly severe pathological form of an otherwise more benign condition (unusual pathogenesis); and (iii) rare early-onset pediatric cases. To date, mutations in 265 genes have been shown to cause PIDs, providing a rich data set for the systematic characterization of cellular and molecular networks involved in the development, activity, and regulation of immune cells during response to infectious or to inflammatory stimuli (see Table S1 in the supplemental information online) [22] [23] [24] . A clinical classification has recently been provided for PIDs where the genetic etiology is known [25] . It includes: (i) combined immunodeficiencies (T and/or B cells); (ii) combined immunodeficiencies with syndromic features; (iii) humoral deficiencies; (iv) diseases of immune dysregulation; (v) defects in phagocytes numbers or function; (vi) defects in innate immunity; (vii) autoinflammatory disorders; and (viii) deficiencies of the complement system. While the majority of mutations affect the development and function of leukocytes, others are inborn errors of metabolisms (in so-called 'house-keeping' proteins) with or without syndromic features [23] vast majority of genetic lesions causing PIDs are highly penetrant and inherited in a recessive fashion. However, a fraction are inherited as autosomal dominant (heterozygotes) with variable penetrance, and associated with either haploinsufficiency, with gain-of-function, or with negative dominance [8, [26] [27] [28] [29] .
The study of genotype/phenotype correlations in PIDs has been extremely productive. It has not only identified host cells and pathways that are essential for general protection against microbial pathogens in general, but also recognized pathways that are surprisingly nonredundant and that are required for response to unique groups of pathogen. On the one hand, several PIDs are very severe, and manifest themselves as broad susceptibility to viral, bacterial, and parasitic pathogens. Examples include severe combined immunodeficiency (SCID) (partial or complete loss of T and B cells) that is caused by mutations in >30 genes, the most frequent being IL2RG, ADA, IL7RA, JAK3, RAG1, RAG2, and CD3 [25, 30] . Likewise, chronic granulomatous disease (CGD) is associated with recurrent bacterial and fungal infections in the presence or absence of neutropenia, and linked to impaired production of oxygen radicals by myeloid cells caused by mutations in constituents of the NADPH oxidase (CYBA, CYBB, NCF1, NCF2, and NCF4) [31] . Another example is CD4 lymphopenia, whose etiology includes deficiency in MAGT1, and which manifests by viral and bacterial infections and histoplasma. On the other hand, some PIDs display very restricted infection susceptibility phenotypes. Mutations in TLR3 cause susceptibility to herpes simplex virus (HSV) and associated encephalitis (HSE) [32] , but nothing else. Remarkably, the same restricted HSE phenotype is found in patients harboring mutations in other members of the TLR3-IFN//b pathways, including TRIF, TRAF3, UNC93B1, and TBK1 [33] . A similar situation is seen with IL17 deficiency, CARD9 deficiency, and some patients with autosomal dominant STAT1 deficiency, who uniformly display a narrow phenotype of chronic mucocutaneous candidiasis (CMC) [34] . Also, defects in the IFNg/IL12 circuit tend to cause a narrow phenotype of susceptibility to infection with environmental mycobacteria, or disseminated BCG infection postvaccination, a syndrome named Mendelian Susceptibility to Mycobacterial Disease (MSMD) [35] . These results highlight the nonredundant nature of the host defense mechanisms against these infections.
Additional insight into different, cell-specific molecular functions of a PID gene product can sometimes be reflected by the heterogeneity of clinical phenotypes associated with different types of mutation in the same gene. For example, heterozygosity for inactivating mutations in STAT1 cause a decrease in protein phosphorylation and DNA binding, resulting in diminished production of IFNg, which is clinically expressed as susceptibility to mycobacterial infections [36] . Conversely, mutations affecting STAT1 coiled-coil and DNA-binding domains lead to an excess of p-STAT1-driven target gene transcription. These heterozygote STAT1 mutations impair nuclear dephosphorylation of p-STAT1, causing both increased transcriptional activity and decreased IL17 production by T cells, which are clinically expressed as susceptibility to CMC, and phenotypically mimicking mutations of the IL17F, IL17RA, and ACT1 genes [37] . Similarly, hemizygosity for loss-of-function mutations in WASP (Wiskott Aldrich Syndrome) cause thrombocytopenia, eczema, decreased T and B cell function, and recurrent infections, while activating WASP mutations cause neutropenia with no risk of infection [38] . Finally, penetrance and expressivity of a specific PID mutation can be dramatically influenced in different patients by additional, yet to be defined, genetic or environmental effects. For example, GATA2 mutations are associated with a constellation of phenotypes in different patients, including familial myelodysplasia, dendritic cells/monocytes/B and NK cell deficiency, and decreased monocytes counts with susceptibility to mycobacteria [39] [40] [41] . Also, patients bearing the same inactivating TYK2 deletion show different phenotypes with or without Hyper IgE syndrome with associated viral, fungal, and BCG infections at clinical presentation in one patient, while another patient with the same mutation had BCGosis and brucellosis with normal IgE levels [42, 43] .
In conclusion, the rapidly increasing list of PID mutations is identifying critical mechanisms of protection against microbial pathogens (see Table S1 in the supplemental information online). In genotype-genotype comparisons (see below), these mutations can also validate loci and associated gene effects in unrelated diseases with a suspected microbial etiology and that have been detected as GWAS loci. This is particularly important when the identity of a morbid gene at such GWAS loci remains elusive due, for example, to linkage disequilibrium (LD) near mapped loci. Concordance between PID genes and GWAS disease loci may provide critical new insight into host cells and pathways that play a role in pathogenesis of an unrelated disease, and may even point to a specific pathogen or group of pathogens as participating in the etiology of this unrelated condition.
Inflammatory Diseases
A strong genetic component has long been established (through familial clustering, gender effect, segregation analyses, and twin studies) for major diseases of inflammation, such as inflammatory bowel disease (IBD), multiple sclerosis (MS), rheumatoid arthritis (RA), Celiac disease (CeD), type I diabetes (T1D), systemic lupus erythematosus (SLE), psoriasis (Pso.), and several other such disorders. Over the past 10 years, the genetic architectures of these diseases have been mapped by GWAS in large cohorts of patients and controls (>10 000), and in different populations. In addition, results from independent GWAS studies have been combined in large meta-analyses (>50 000 patients), resulting in the mapping and validation of hundreds of genetic risk loci[ 4 _ T D $ D I F F ] (polygenic diseases). Public GWAS databases to which the reader is referred (NHGRI GWAS Catalog, GWASdb, Gen2Phen, GWAS Central, and ImmunoBase) provide regular updates; at the last count, >600 loci (genome-wide significance threshold p <5 Â 10
) affecting susceptibility to chronic inflammatory and/or autoimmune diseases had been mapped by this approach [44] [45] [46] [47] . As reviewed below, many of these loci are shared between different diseases, while others appear to be disease specific. The careful scrutiny of the shared genetic risk provides valuable insight into the host mechanisms that underlie the process of pathological inflammation, while disease-specific pathways may reflect specific gene-environment interactions unique to that disease and/or tissue affected. An important caveat of the GWAS data sets is that, with the exception of HLA, the effect size of individual loci is small with low odds ratios. This may be caused by a number of factors, including complexity of the genetic determinants, heterogeneity in the disease phenotype, whose current definition is restricted to a clinical end-point, and complex gene-environment interactions.
The deepest genetic data sets come from IBD [13] , MS [17, 18] , and RA [14] . IBD encompasses both ulcerative colitis (UC) and Crohn's disease (CD), two related intestinal inflammatory conditions with distinct clinical and pathological manifestations. The most recent meta-analysis of 75 000 cases and controls detected a total of 163 genetic risk loci, 110 of them in common in both UC and CD, with an additional 23 UC-specific loci, and 30 CD-specific loci, with strong candidate genes identified for 53% of the loci [13] . About one-third (n = 66) of the loci were also found to be shared in common with other inflammatory and autoimmune diseases. Cell-specific gene expression studies show that the major cell type 'hosting' these genetic effects is primarily dendritic cells followed by CD4 + T cells and NK cells, while biological network analysis pointed to cytokine production, lymphocytes numbers and activation, and response to bacterial products as the key associated response pathways in these cells [13] . The most recent meta-analysis of MS genetic risk combining GWAS results and independent immunochip genotyping (80 000 cases and controls), identified a total of 110 non-MHC loci [18] . Of those, 97 variants fell within 50 kb of genes loosely annotated as immune function (prior annotation, organ-and cell-specific expression), with 35 linked to the GO term 'immune system process'. Importantly, the genetic architecture solved in this analysis identified a clear overlap with risk loci for IBD (17%), UC (13%), CD (15%), and primary biliary cirrhosis (10%), as well as CeD (7%), RA (4.5%), and 3.6% with Pso.
[18]. For RA, a recently published meta-analysis of GWAS and immunochip data of >30 000 cases and 73 000 controls identified a total of 101 non-MHC genetic risk loci containing a minimum aggregate number of 377 genes (defined by LD) [14] . Interestingly, almost two-thirds of the mapped genetic risk loci are shared with other immune-related diseases. Forty-four loci show cis-regulatory variants [expression QTLs (eQTLs)] that are active in CD4 + T cells, in CD14 + cells, or in PBMCs. Pathway and gene expression analysis also shows significant enrichment of T cell-and B cell-dependent pathways and of cytokine signaling pathways [14] . Finally, a recent study defined cis-regulatory regions in a variety a hematopoietic cells [48] . It found that $60% of GWAS loci for inflammatory diseases are associated with cis-regulatory regions that display disease-associated and cell type-specific effects (for example, CD and UC hits have strong association with T cell enhancers, whereas RA, MS, and SLE are also linked to B cells).
The careful delineation of the shared genetic risk in inflammatory and other immune related diseases is of particularly interest to understand the basic mechanisms of pathological inflammation, and to identify possible novel drug targets of broad therapeutic value. A combined analysis of these GWAS data sets for 22 of the most common inflammatory diseases identified a total of 439 unique genetic risk loci; of these, 203 (46%) are shared with at least one other inflammatory disease, 88 loci are shared by 2 diseases, 39 by 3 diseases, 34 by 4 diseases, while a surprising 42 loci (9.6% of the loci tested) were shared in common by 5 or more diseases ( Figure 1 , Key Figure) (see Table S2 in the supplemental information online). The Circos plot shown in Figure 1 illustrates the genetic loci shared by 4 or more inflammatory diseases. In comparing the extent of overlap in genetic risk loci across the different diseases, it is important to remember that this overlap will be affected by the number of loci mapped in each disease, which is in part determined by the number of patients analyzed in each study (statistical power), and the strength of the genetic component in each disease. (To maximize the capture of shared genetic loci across different inflammatory diseases, we used a reduced statistical threshold and p value <1 Â 10 -5 ). Hence, the overlaps identified in Figure 1 (see Table S2 in the supplemental information online) are likely to be underestimates, negatively influenced by the relative smaller size of certain GWAS studies. Conversely, the bias for informative SNPs at 'immune genes' in the immunochip [49] used in a few of the GWAS may positively affect the size of the genetic overlap between mapped loci in different diseases. Among these 76 ubiquitous genetic loci (detected in 4 or more diseases) (Figure 1 ), the HLA-DQ/HLA-DR region of the MHC (or specific portions of it) was most prominent, being positive for association in all of the 22 diseases tested. Other shared loci in this group related to cell types, responses, and pathways already known for relevance to pathogenesis, including: (i) pattern recognition receptors of the innate immune system and associated signaling cascades; (ii) antigen processing and presentation, production of cytocidal species, and secretion of proinflammatory mediators by myeloid cells; (iii) T and B lymphocyte maturation, including control of autoreactive T and B cells; (iv) antigen receptors of T and B cells for recognition in the context of Class I or Class II MHC; and (v) production of proinflammatory cytokines, and associated regulation of Th1, Th17, and Treg polarization of the immune response. Interestingly, about a quarter of these 76 most commonly shared loci do not show a clear biological candidate.
Genetic Intersections between Primary Immunodeficiencies and Inflammatory Diseases
The selective pressure imposed by pathogens during human evolution has shaped the host defense gene repertoire, but this has been suggested to have a fitness cost predisposing to inflammatory diseases (reviewed in [50] ). Interestingly, we note a significant overlap between GWAS loci for inflammatory diseases (LD regions from the GWAS Catalog) and genes mutated in PIDs, with 80 of the 265 identified PID genes (30%) falling within boundaries of GWAS loci (Table 1 ). This overlap is statistically highly significant, when using 10 independent training sets of 250 genes as controls (p value compared with random expectations = 3.5 Â 10 -12 ; Fisher's exact test). In addition, over half of these PID genes (44/80) are associated with susceptibility to more than one inflammatory disease. The greatest overlap is with CD (34), UC (30), RA (24) , and MS (23) The outside rim identifies the 22 human chromosomes in individual colors. The inflammatory diseases surveyed are identified and depicted by concentric circles onto which the mapped loci shared by 2 or more diseases are positioned (blue dots). Two genetic risk loci are considered overlapping when the most significant SNP at a given locus maps <50 kb from another locus (see Table S2 in the supplemental information online). Red intersecting lines identify loci that are shared in common by 4 or more of the diseases surveyed. An abbreviated list of genes in linkage disequilibrium (LD; the number of genes in LD are in brackets) at each locus radiates to the outer part of the plot. Abbreviations: AA, alopecia areata; AD, atopic dermatitis; AS, ankylosing spondylitis; Asth., asthma; Behc., Behçet's disease; CD, Crohn's disease; CeD, celiac disease; Grav., Graves' disease; Hypoth., hypothyroidism; Kawa., Kawasaki disease; MS, multiple sclerosis; Narc., narcolepsy; Neph., nephropathy; PBC, primary biliary cirrhosis; Pso., psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, systemic sclerosis; T1D, type 1 diabetes; T2D, type 2 diabetes.; UC, ulcerative colitis; Vit., vitiligo. overlaps represent a 'who's who' of immune genes ( Figure 2 ). This list contains master transcription factors (STAT1, STAT2, STAT3, STAT4, STAT5B, AIRE, IRF7, IRF8, NFkB, IKZF1, and CIITA) and regulatory proteins (ATM, CASP8, and CASP10) involved in ontogeny, and maturation of myeloid cells and lymphoid cells; proteins participating in antigen recognition, processing, and presentation (Class I MHC, Class II MHC, NOD2, TAP1, TAP2, and CD40), inflammasome activation platforms (CARD9, CARD11, and TYK2), and antimicrobial function (NCF2 and NCF4) of myeloid cells. The list also includes a number of pro-and anti-inflammatory cytokines (IL10, IL12, and IL21) as well as cytokine receptors expressed by lymphoid and myeloid cells (IL2R, IL7R, IL10R, IL12R, IFNGR1, INFGR2, and CXCR4), and protective serum molecules from the complement system (C2, C3, C5, CFB, CFH, and ITGAM). Therefore, it is obvious that the same cellular and molecular mechanisms that are required for protection against infections may also be involved, through sustained engagement, in onset or progression of inflammatory diseases. Figure 3 illustrates some of these proteins and associated pathways in the immune pathogenesis of IBD, MS, and RA. Although many of the genes at the PID/GWAS interface are associated with general and severe immunodeficiencies, others are associated with narrower immunodeficiency phenotypes, perhaps pointing at specific host responses and unique host-microbe interactions that may be relevant to the inflammatory diseases where they behave as genetic risks. For example, mutations in STAT1 (IBD, SLE, RA, PBC, and SS), IFNGR1 (MS), IFNGR2 (CD and RA), IL12B (IBD, MS, Pso., and AS), IL12R (MS), IRF8 (IBD, MS, RA, SLE, PBC, and SS) and TYK2 (many diseases, including MS) are associated with MSMD, a fairly narrow form of immunodeficiency revealed after BCG vaccination and associated with impaired Th1 response (IFNg/IL12 circuit). Interestingly, the detected overlap between MSMD genes and MS loci, with unique association of IFNGR1 and IL12R, is supporting a role of IFNg/IL12 loop in the etiology of this debilitating autoimmune disorder. Likewise, mutations in TRAF3IP2 (UC/CD, and Pso.), and CARD9 (UC/CD, and AS) cause a narrow invasive fungal infection phenotype in humans. Finally, TICAM1 mutations lead to herpes simplex encephalitis caused by natural HSV infection, while this gene is associated with vitiligo in GWAS studies. It is tempting to speculate that coincidence between (i) gene mutations causing narrow immunodeficiencies restricted to one group of pathogens and (ii) GWAS loci for one or several inflammatory diseases, may point to geneenvironment interactions possibly with the same group of microbes involved in the etiology of inflammatory diseases.
Another informative data set to consider are genes mutated in unique cases of very early-onset pediatric IBD (VEO-IBD), the list of which shows significant intersection with genes mutated in PIDs (Table 1 ). This group includes diverse proteins that play a critical role not only in sensing of microbial products at the mucosal barrier, but also in microbicidal activity, as well as in activation and amplification of proinflammatory responses (illustration in Figure 2 ). Selected examples include: (i) ADAM17 (metalloprotease that cleaves TNF/, L-selectin, and EGFR ligands), a gene mutated in patients with neonatal onset of IBD [51] ; (ii) IKBKG encoding nuclear KB essential modulator protein (NEMO) associated with enterocolitis with villous atrophy and epithelial cell shedding [52, 53] ; (iii) hemizygote mutation for X-linked inhibitor of apoptosis protein gene (XIAP) in pediatric IBD [54] [55] [56] [57] ; (iv) a homozygote mutations in the PIK3R1 gene in a patient with colitis and B cell deficiency [58, 59] ; (v) TTC7A mutations in patients with intestinal atresia, enterocolitis, and combined immunodeficiency [60, 61] ; (vi) FOXP3 variants in individuals of European ancestry presenting with an early-onset and atypical form of IBD [62] ; (vii) multiple variants in subunits of the NADPH oxidase complex [63] ; (viii) hypermorphic PLCG2 allele in a familial form of dominant inflammatory disease, including enterocolitis [64] ; (ix) CTLA4 missense mutations (CTLA-4 Y60C) have been associated with severe, early-onset CD with increased T cell activation and an increased ratio of memory to naive T cells [65] ; and finally, (x) rare variants in IL10 and its receptors IL10RA and IL10RB, and IL21 genes associated with chronic intestinal inflammation in early childhood [59, [66] [67] [68] [69] . Table 1 ; red lettering) involved in the functional crosstalk between myeloid and lymphoid cells, including antigen recognition, capture, processing, and presentation to T cells, and associated responses are represented. Impaired regulation in monogenic disorders can affect adaptive immune responses (such as CD45, OX40, ICOS, and CD40 deficiencies) by effector cells, peptide presentation by antigen-presenting cells (such as PSMB8 and TAP1/2 deficiencies) or bacterial sensing (NOD2 and CARD9) exemplify the interaction network between PID and inflammatory diseases (for further details, refer to the main text).
patients with OX40 deficiency provides a testable hypothesis that this gene is responsible for the effect in IBD. Similar situations occur for loci on Chr2 (204 Mb, 3 genes in LD group, association with 7 diseases; ICOS), and Chr12 (63-66 Mb, 9 genes in LD, 4 diseases; TNFRSF1A). Interestingly, certain PID genes map to GWAS loci for which a different positional candidate had been previously proposed based on general ontology annotation. A locus on Chr21 (45 Mb) was associated with disease risk in CD, UC, CeD, and RA; from the list of 9 genes in LD at this locus, ICOSLG was previously identified as the best candidate based to its co-stimulatory function in T cells. However, the discovery that this Chr21 locus contains the PID gene and transcription factor AIRE (Table 1) suggests an additional candidate gene to be considered for the effect. The same situation arises for other GWAS loci: that is, the Chr15 locus (91 Mb; identified in CD, UC, RA, and T2D), where the PID gene BLM must be considered in addition to the current leading candidate CRTC3, and the Chr20 locus (62 Mb; CD, UC, and MS), which The study of tens of thousands of patients by GWAS and using SNP arrays of increasing density and informative content, have identified a rich genetic architecture in inflammatory diseases. Of the >400 unique risk loci discussed in our review, identifying the causative gene is limited in part by the presence of LD near the mapped loci. LD occurs when chromosomal segments containing several disease-linked contiguous markers (SNPs) are inherited together as a block (haplotype blocks), with the lack of recombination making it difficult to narrow down the exact position of the causative genetic lesion. On the other hand, the rapid identification of rare coding mutations in PID patients by WES is providing a deep data set for genes that are essential for protection against infections. Merging the 2 data sets may help identify morbid genes at or near GWAS loci.
In the example shown ( Figure I ), multiple SNPs on human 2q24.2 are associated with inflammatory or autoimmune diseases: (i) rs2111485 is associated with CD, UC [13] , systemic lupus erythematosus (SLE) [70] , and vitiligo [71] ; (ii) rs1990760 with T1D [72] , IgA antibody deficiency [73] , and Grave's disease [74] ; and (iii) rs17716942 with psoriasis [75] . LD in this region defines an interval that contains 5 or 6 candidate genes, two of which are expressed in peripheral blood cells and associated with immune function. Interestingly, rs2111485 behaves as a cis-acting eQTL that affects IFIH1 mRNA expression [70] . In addition, application of a 'Myeloid Inflammatory Score' (MIS) [76] that considers DNA binding and transcriptional activation by proinflammatory transcription factors points to Ifih1 as the top positional candidate in the LD interval ( Figure IB) . Interestingly, mice carrying a gain-of-function mutation in IFIH1 develop spontaneous lupus-like symptoms [77] . Moreover, rare IFIH1 variants have been associated with risk of T1D and SLE [78] [79] [80] [81] .
IFIH1 encodes the cytosolic viral RNA receptor MDA5, a member of the RIG-I-like receptor family, that mediates the induction of a type I interferon for antiviral immunity (reviewed in [10] ). The binding of long dsRNA to MDA5 helicase domain ( Figure IC) stimulates signaling through the CARD domain-associated adaptor molecule IPS-1/MAVS, itself a risk locus for asthma [82] ; MDA5-IPS-1 signaling is kept under control by the negative regulator ADAR1 [83] . The activated signaling cascade includes several genes implicated in inflammatory diseases by GWAS or mutated in PID (genes in blue and red; Figure ID ; see Table S2 in the supplemental information online). MDA5 helicase domain sequence variants have been found in Aicardi-Goutières syndrome (AGS) patients (elevated type I interferon levels and signaling) [84, 85] . All identified mutations are autosomal dominant and cause a stabilization of the helicase domain with dsRNA. MDA5 variants have also been detected in SLE patients, consistent with the fact that some of these AGS patients develop lupus-like symptoms [81] . immune-related diseases (labeled in red over the associated SNP). The SNP rs2111485 has been shown to behave as a cis-eQTL for expression of IFIH1 mRNA in response to IFNg [86] . The mRNA expression of genes in the interval in PBMC is shown (RNA-seq tracks density) over individual exons [87] . (B) Illustration of the corresponding mouse locus, including the position of the genes, the myeloid inflammation score [76] contains both the PID gene RTEL1 and the published candidate TNFRSF6B, and, finally, the Chr8 locus (91 Mb; CD) where the PID gene NBN gene must be considered along with RIPK2. Finally, an interesting situation emerges from the analysis of a locus on Chr12 (109-113 Mb; 6 diseases), which contains a total of 57 genes in LD, including the UNG (low level of circulating IgG and IgA) and the MVK (autoinflammatory disorder caused by mevalonate kinase deficiency) genes whose inactivation causes PIDs. Hence, the GWAS hit at this location in 6 diseases may be due to the independent effect of each gene in specific diseases, an effect that cannot be segregated due to LD; alternatively, it is interesting to consider the possibility that alterations at both genes (either coding variants, or regulatory modulation/eSNPs) may be required to impact inflammatory pathologies.
Concluding Remarks
In conclusion, the explosion of genome technologies has dramatically increased our understanding of the genetic architecture of human susceptibility to infections and to inflammatory conditions[ 5 _ T D $ D I F F ] (see Outstanding Questions). Combined analysis of these two data sets identifies a significant overlap composed of genes and proteins that are required for protection against infections but whose engagement is associated with pathological inflammation. The genes/ proteins identified at this interface may represent valuable new targets for drug discovery. This genetic intersection additionally suggests that, although strong mutations and/or inactivation (rare variants) of intersecting genes may independently cause severe diseases (PIDs), their more subtle modulation through the action of common variants in the presence of a persistent tissue insult may contribute to chronic inflammation. Because these two data sets (WES in PIDs and GWAS of inflammatory diseases) continue to expand, it is likely that the intersection between them will continue to grow, increasing its informative content. Likewise, combined analysis of GWAS and PID data sets may help prioritize and/or validate candidate genes identified by sequencing or mapping. These analyses may also point to signal transduction pathways, protein products that physically interact, genes sharing the same expression pattern, and/or regulated by cis or trans eQTL, and whose further modulation may be associated with disease. Finally, the emergence of novel methods for high efficiency genome editing (CRISPR-Cas9) opens the door to the creation of informative animal models where the immunological and biochemical basis of these genes function can be studied in well-defined environments.
Outstanding Questions
How can we identify causative disease genes in complex human genomic data sets? GWAS mapping relies on markers that are often in LD on large genome segments containing tens of genes. The top linked SNP rarely is a loss of function, often mapping to noncoding regions. Both complicate the identification of the 'morbid' gene and associated genetic lesions. The functional annotation of GWAS loci using the genetics intersections described in this review may help in this identification. A related problem arises from WES and whole-genome sequencing of sporadic cases; these identify numerous 'private' variants with variable allele frequencies, incomplete penetrance, and unknown mode of inheritance, and whose contribution to disease is difficult to establish. Systematic validating one gene at a time is required for many such loci. Efficient genome-editing techniques (CRISPRcas9) applied to human cell lines or to mouse models will soon provide a systematic catalog of such 'morbid' genes in which their contribution to disease can be tested in a well-controlled environment.
What is the impact of environmental factors on disease? Gene-environment interactions are the next problem to solve for inflammatory diseases where a microbial component is established or strongly suspected. Studies investigating interactions between lifestyle, diet, and genetic factors are underway to address this problem. Studies in mouse models reconstituted with human microflora should also help address this issue.
What is the impact of gene-gene interactions in disease? A favored conceptual framework is that human diseases are caused by rare or common variants in a fixed set of genes, and such variants cause disease with variable penetrance. Genetic studies in flies, worms, fish, and mice have long established that weak mutations in independent members of one pathway (signaling cascade, physically interacting proteins, co-regulated genes, etc.) can mimic the effect of a strong mutation in the said pathway or 'complementation group'. Such gene-gene interactions are almost certainly at play in humans, but identifying them will be a challenge.
